Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 3/2020

01-09-2020 | Liver Transplantation | Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

Budd-Chiari Syndrome: Anticoagulation, TIPS, or Transplant

Authors: Marta Magaz, Guillem Soy, Juan Carlos García-Pagán

Published in: Current Hepatology Reports | Issue 3/2020

Login to get access

Abstract

Background and Purpose of Review

Budd-Chiari syndrome (BCS) is a rare vascular liver disease caused by the obstruction of the hepatic venous outflow tract that may be fatal and is not adequately treated. We aim to review the current management of BCS.

Methods

Analysis of recent literature by using PubMed, EMBASE, and Medline databases.

Findings

Recommended treatment of BCS is based in an stepwise progressively invasive management strategy that includes anticoagulation and treatment of the underlying prothrombotic risk factors and percutaneous revascularization in short hepatic or inferior vena cava stenosis as first step then, if failure, transjugular intrahepatic portosystemic shunt reserving liver transplantation to those patients that do not respond to previous steps.

Conclusions

Early diagnosis and treatment have improved the outcome of patients with BCS. However, BCS management remains a challenge, requiring multidisciplinary teams in referral centers with BCS expertise.
Literature
1.
Garcia-Pagán JC, Buscarini E, Janssen HLA, Leebeek FWG, Plessier A, Rubbia-Brandt L, et al. EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol. 2016;64:179–202.CrossRef
2.
Martín-Llahí M, Albillos A, Bañares R, Berzigotti A, García-Criado MÁ, Genescà J, et al. Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver. Gastroenterol. Hepatol. 2017;40:538–80.
3.••
Simonetto DA, Singal AK, Garcia-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG clinical guideline: disorders of the hepatic and mesenteric circulation. Am. J. Gastroenterol. 2020;115:18–40. Recent evidence-based consensus American clinical guidelines issued by major specialty societies providing guidance for clinicians on up-to-date care and management of BCS among other vascular liver diseases.
4.
Angeli P, Bernardi M, Villanueva C, Francoz C, Mookerjee RP, Trebicka J, et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–60.CrossRef
5.•
Hernández-Gea V, De Gottardi A, Leebeek FWG, Rautou P-E, Salem R, Garcia-Pagan JC. Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis. J. Hepatol. 2019;71:175–199. Important systematic review summarizing the diagnosis and management of BCS.
6.
Oblitas CMA, Galeano-Valle F, Toledo-Samaniego N, Pinilla-Llorente B, Del Toro-Cervera J, Álvarez-Luque A, et al. Budd-Chiari syndrome in Behçet’s disease successfully managed with immunosuppressive and anticoagulant therapy: a case report and literature review. Intractable Rare Dis Res. 2019;8:60–6.CrossRef
7.
Armstrong MJ, Frederick HM, Neil D, Brown R, Cain O, Tripathi D. Review article : a multidisciplinary approach to the diagnosis and management of Budd - Chiari syndrome. 2019;
8.
Smalberg JH, Arends LR, Valla DC, Kiladjian J-J, Janssen HLA, Leebeek FWG. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120:4921–8.CrossRef
9.
Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22–33.PubMed
10.•
Sharma A, Goel A, Moses V, Keshava SN, Zachariah UG, Elias E, et al. Anticoagulating Budd–Chiari syndrome patients presenting with variceal bleed: a retrospective study. J. Gastroenterol. Hepatol. 2020;jgh.14971. An encouraging study anticoagulation treatment seems safe even in those patients who have had variceal bleeding.
11.•
Sharma S, Kumar R, Rout G, Gamanagatti SR, Shalimar. Dabigatran as an oral anticoagulant in patients with Budd–Chiari syndrome post-percutaneous endovascular intervention. J. Gastroenterol. Hepatol. 2019;jgh.14843. A recent study that shows that Direct oral Anticoagulants may be safe in BCS patients.
12.
De Gottardi A, Trebicka J, Klinger C, Plessier A, Seijo S, Terziroli B, et al. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int. 2017;37:694–9.CrossRef
13.
Chaudhary R, Sharma T, Garg J, Sukhi A, Bliden K, Tantry U, et al. Direct oral anticoagulants: a review on the current role and scope of reversal agents. J Thromb Thrombolysis. 2020;49:271–86.CrossRef
14.
Sharma S, Texeira A, Texeira P, Elias E, Wilde J, Olliff S. Pharmacological thrombolysis in Budd Chiari syndrome: a single centre experience and review of the literature. J Hepatol. 2004;40:172–80.CrossRef
15.
Smalberg JH, Spaander MVMCW, Jie K-SG, Pattynama PMT, van Buuren HR, van den Berg B, et al. Risks and benefits of transcatheter thrombolytic therapy in patients with splanchnic venous thrombosis. Thromb Haemost. 2008;100:1084–8.CrossRef
16.
Han G, Qi X, Zhang W, He C, Yin Z, Wang J, et al. Percutaneous recanalization for Budd-Chiari syndrome: an 11-year retrospective study on patency and survival in 177 Chinese patients from a single center. Radiology. 2013;266:657–67.CrossRef
17.
Valla D, Hadengue A, el Younsi M, Azar N, Zeitoun G, Boudet M, et al. Hepatic venous outflow block caused by short-length hepatic vein stenoses. Hepatology. 1997;25:814–9.CrossRef
18.
Seijo S, Plessier A, Hoekstra J, Era AD, Mandair D. Rifai K, et al. Good long-term outcome of Budd-Chiari syndrome with a step-wise management. 2012:1962–8.
19.
Tripathi D, Sunderraj L, Vemala V, Mehrzad H, Zia Z, Mangat K, et al. Long-term outcomes following percutaneous hepatic vein recanalization for Budd-Chiari syndrome. Liver Int. 2017;37:111–20.CrossRef
20.
Wang Q, Li K, He C, Yuan X, Luo B, Qi X, et al. Angioplasty with versus without routine stent placement for Budd-Chiari syndrome: a randomised controlled trial. Lancet Gastroenterol. Hepatol. 2019;4:686–97.PubMed
21.
Ferrusquía-Acosta J, Hernández-Gea V, Turón F, García-Pagán JC. Budd-Chiari syndrome with short-length stenosis: still room for the angioplasty and wait-and-see strategy. Lancet Gastroenterol Hepatol. 2019;4:823.PubMed
22.
Bi Y, Chen H, Ding P, Ren J, Han X. Comparison of retrievable stents and permanent stents for Budd–Chiari syndrome due to obstructive inferior vena cava. J Gastroenterol Hepatol. 2018;33:2015–21.PubMed
23.
Montano-Loza AJ, Tandon P, Kneteman N, Bailey R, Bain VG. Rotterdam score predicts early mortality in Budd-Chiari syndrome, and surgical shunting prolongs transplant-free survival. Aliment Pharmacol Ther. 2009;30:1060–9.PubMed
24.
Langlet P, Escolano S, Valla D, Coste-Zeitoun D, Denie C, Mallet A, et al. Clinicopathological forms and prognostic index in Budd-Chiari syndrome. J Hepatol. 2003;39:496–501.PubMed
25.
Murad SD, Valla D-C, de Groen PC, Zeitoun G, Hopmans JAM, Haagsma EB, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology. 2004;39:500–8.
26.
Rautou P-E, Moucari R, Escolano S, Cazals-Hatem D, Denié C, Chagneau-Derrode C, et al. Prognostic indices for Budd–Chiari syndrome: valid for clinical studies but insufficient for individual management. Am J Gastroenterol. 2009;104:1140–6.PubMed
27.
Rautou P, Moucari R, Cazals–Hatem D, Escolano S, Denié C, Douarin L, et al. Levels and initial course of serum alanine aminotransferase can predict outcome of patients with Budd–Chiari syndrome. Clin. Gastroenterol. Hepatol. 2009;7:1230–1235.
28.
Wang H-W, Shi H-N, Cheng J, Xie F, Luo Y-K, Tang J. Real-time shear wave elastography (SWE) assessment of short- and long-term treatment outcome in Budd-Chiari syndrome: a pilot study. PLoS One. 2018;13:e0197550.PubMedPubMedCentral
29.
Zeitoun G, Escolano S, Hadengue A, Azar N, El Younsi M, Mallet A, et al. Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology. 1999;30:84–9.PubMed
30.
Shaked A, Goldstein RM, Klintmalm GB, Drazan K, Husberg B, Busuttil RW. Portosystemic shunt versus orthotopic liver transplantation for the Budd-Chiari syndrome. Surg Gynecol Obstet. 1992;174:453–9.PubMed
31.
Slakey DP, Klein AS, Venbrux AC, Cameron JL. Budd-Chiari syndrome: current management options. Ann Surg. 2001;233:522–7.CrossRef
32.
Langlet P VD. Is surgical portosystemic shunt the treatment of choice in Budd-Chiari syndrome? Acta Gastroenterol Belg. 2002;
33.
Bachet J-B, Condat B, Hagège H, Plessier A, Consigny Y, Belghiti J, et al. Long-term portosystemic shunt patency as a determinant of outcome in Budd–Chiari syndrome. J Hepatol. 2007;46:60–8.CrossRef
34.
Panis Y, Belghiti J, Valla D, Benhamou JP, Fékété F. Portosystemic shunt in Budd-Chiari syndrome: long-term survival and factors affecting shunt patency in 25 patients in Western countries. Surgery. 1994;115:276–81.PubMed
35.
Serin KR, Tekant Y, Emre A. Is there still a role for surgical shunts in the treatment of Budd-Chiari syndrome? A 25-year experience. J Gastrointest Surg. 2020;24:1359–65.CrossRef
36.
Mancuso A. Timing of transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: an Italian hepatologist’s perspective. J Transl Intern Med. 2017;5:194–9.CrossRef
37.
Hernández-Guerra M, Turnes J, Rubinstein P, Olliff S, Elias E, Bosch J, et al. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology. 2004;40:1197–202.CrossRef
38.
Garcia–Pagán JC, Heydtmann M, Raffa S, Plessier A, Murad S, Fabris F, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology. 2008;135:808–815.
39.
Hayek G, Ronot M, Plessier A, Sibert A, Abdel-Rehim M, Zappa M, et al. Long-term outcome and analysis of dysfunction of transjugular intrahepatic portosystemic shunt placement in chronic primary Budd-Chiari syndrome. Radiology. 2017;283:280–92.CrossRef
40.
Mancuso A. In favour of early intervention for Budd–Chiari syndrome. Eur J Gastroenterol Hepatol. 2016;28:850–1.PubMed
41.
Doğrul AB, Yankol Y, Mecit N, Kanmaz T, Acarlı K, Kalayoğlu M. Orthotopic liver transplant for Budd-Chiari syndrome: an analysis of 14 cases. Exp Clin Transplant. 2016;14:641–5.PubMed
42.
Shalimar, Kumar A, Kedia S, Sharma H, Gamanagatti SR, Gulati GS, et al. Hepatic venous outflow tract obstruction: treatment outcomes and development of a new prognostic score. Aliment. Pharmacol. Ther. 2016;43:1154–1167.
43.
Mentha G, Giostra E, Majno PE, Bechstein WO, Neuhaus P, O’Grady J, et al. Liver transplantation for Budd–Chiari syndrome: a European study on 248 patients from 51 centres. J Hepatol. 2006;44:520–8.PubMed
44.
Krawczyk M. Myeloproliferative neoplasms and recurrent thrombotic events in patients undergoing liver transplantation for Budd-Chiari syndrome: a single-center experience. Ann Transplant. 2014;19:591–7.PubMed
Metadata
Title
Budd-Chiari Syndrome: Anticoagulation, TIPS, or Transplant
Authors
Marta Magaz
Guillem Soy
Juan Carlos García-Pagán
Publication date
01-09-2020

Other articles of this Issue 3/2020

Current Hepatology Reports 3/2020 Go to the issue

Autoimmune, Cholestatic, and Biliary Diseases (S Gordon and CL Bowlus, Section Editors)

IgG4-Related Sclerosing Cholangitis

Hepatitis B (JK Lim, Section Editor)

Management of Acute Hepatitis B Virus Infection

Hepatitis B (JK Lim, Section Editor)

Targeting Viral cccDNA for Cure of Chronic Hepatitis B

Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

Portal Hypertensive Ascites: Current Status

Hepatitis B (JK Lim, Section Editor)

Role of Core/Capsid Inhibitors in Functional Cure Strategies for Chronic Hepatitis B

Management of the Cirrhotic Patient (A Cardenas and P Tandon, Section Editors)

Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits